WO2021179884A1 - 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 - Google Patents
具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2021179884A1 WO2021179884A1 PCT/CN2021/076726 CN2021076726W WO2021179884A1 WO 2021179884 A1 WO2021179884 A1 WO 2021179884A1 CN 2021076726 W CN2021076726 W CN 2021076726W WO 2021179884 A1 WO2021179884 A1 WO 2021179884A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- alkyl
- acceptable salt
- substituted
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 125000002897 diene group Chemical group 0.000 title claims abstract description 11
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 6
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 25
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000005011 alkyl ether group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Chemical group 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000006413 ring segment Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- -1 oleanolic acid derivative compound Chemical class 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 description 16
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 8
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 8
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 229940125904 compound 1 Drugs 0.000 description 8
- 229940100243 oleanolic acid Drugs 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000006937 anti-inflammatory bioactivity Effects 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 5
- 229960004623 paraoxon Drugs 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 4
- 229910000497 Amalgam Inorganic materials 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- RJCWBNBKOKFWNY-IDPLTSGASA-N n-[(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(NC(=O)C(F)(F)C)CC[C@]21C RJCWBNBKOKFWNY-IDPLTSGASA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 0 CC(C)(CC[C@]1(*)CC[C@@]2(C)[C@]3(C)CC[C@@]4C(C)(C)C5=O)C[C@]1C2=C(**)C=C3[C@@]4(C)C=C5C#N Chemical compound CC(C)(CC[C@]1(*)CC[C@@]2(C)[C@]3(C)CC[C@@]4C(C)(C)C5=O)C[C@]1C2=C(**)C=C3[C@@]4(C)C=C5C#N 0.000 description 3
- 229940122601 Esterase inhibitor Drugs 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002329 esterase inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- TXGZJQLMVSIZEI-UQMAOPSPSA-N Bardoxolone Chemical compound C1=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5[C@H]4C(=O)C=C3[C@]21C TXGZJQLMVSIZEI-UQMAOPSPSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 101150116862 KEAP1 gene Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- NGDUXZPCAJWHOW-UHFFFAOYSA-N 3,3,5,5-tetramethyl-4h-pyrazole Chemical compound CC1(C)CC(C)(C)N=N1 NGDUXZPCAJWHOW-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HTMGQIXFZMZZKD-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinoline Chemical compound N1=CC=C2CCCCC2=C1 HTMGQIXFZMZZKD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000025443 POZ domain binding proteins Human genes 0.000 description 1
- 108091014659 POZ domain binding proteins Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229950002483 bardoxolone Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WBGPNPZUWVTYAA-UHFFFAOYSA-N methane;dihydrochloride Chemical compound C.Cl.Cl WBGPNPZUWVTYAA-UHFFFAOYSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- FOEYMRPOKBCNCR-UHFFFAOYSA-N spiro[2.5]octane Chemical compound C1CC11CCCCC1 FOEYMRPOKBCNCR-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention belongs to the field of medicinal chemistry, and specifically relates to an oleanolic acid derivative compound for preventing and treating inflammation-related diseases and tumor-related diseases, and a preparation method and application thereof.
- Natural terpenoids and derivatives have unique chemical structures and biologically active properties, and are one of the important sources for the development of new small molecule drugs.
- Paclitaxel from Bristol-Myers Squibb and Docetaxel from Sanofi although they have very similar taxane terpenoid structures, have their own characteristics in terms of pharmacokinetics, safety, and clinical application. Features [Practical Medicines and Clinics, 2010,4,281-283].
- oleanane terpenoids such as oleanolic acid
- have a wide range of biological activities such as antioxidant and anti-inflammatory.
- Oleanolic acid is approved in my country for the adjuvant treatment of clinical liver diseases (such as hepatitis).
- oleanolic acid has weak anti-inflammatory and other biological activities, high fat solubility and poor water solubility, and other shortcomings, which limit its clinical application.
- the drug has not been approved for marketing by the United States, Europe and other drug regulatory authorities.
- a series of derived oleanolic acid derivatives such as RTA401, RTA402 and RTA408, are compounds with strong biological activity [J.Med.Chem.2000,43,4233-4246]. Such compounds can be cytoprotective agents and inhibitors of cell inflammatory processes at low concentrations, and inhibit cell proliferation and promote apoptosis at high concentrations [Nat. Rev. Cancer, 2007, 7, 357-369]. Studies have shown that the mechanism of action of this type of compound is also very complicated, and there are many potential targets.
- Keap1-NRF2 Multiple inflammation-related targets and signaling pathways including Keap1-NRF2 have been proven [Nat.Rev.Cancer,2007,7,357–369; J.Am.Soc.Nephrol.2012,1663-1673; PLOS ONE,2014, 9,e98896] participate in it.
- the first type of compounds is mainly focused on the A ring, the preferred candidate compound RTA401 (also known as CDDO, Bardoxolone), namely 2-cyano-3,12-dioxole-1,9(11)-two Ene-28-acid; and RTA402 (also known as CDDO-Me, Bardoxolone methyl), which is 2-cyano-3,12-dioxole-1,9(11)-diene-28-methyl acid .
- RTA401 also known as CDDO, Bardoxolone
- RTA402 also known as CDDO-Me, Bardoxolone methyl
- RTA402 is not a simple methyl ester prodrug of RTA401.
- Reata Company advances both RTA401 and RTA402 into clinical trials and applies them in different indications. For example, in clinical trial NCT00322140, RTA401 was used to treat solid tumors and lymphomas, and in clinical trial NCT03749447, RTA402 was used to treat chronic kidney disease.
- the C ring is also a key area that affects the activity and druggability of the compound.
- the C ring of oleanane also has unique chemical properties.
- the ethylenic bond of ring A of RTA402 can be reduced by catalytic hydrogenation at atmospheric pressure, while the ethylenic bond of ring C is very stable to catalytic hydrogenation.
- Reata Company conducts special research on the C ring, such as saturating unsaturated ethylenic bonds [CN102164941B]. Although the safety of the compound is improved, the biological activity is reduced, and it has not been selected for clinical research so far.
- the present invention provides an oleanane compound with a C ring having a conjugated diene rigid structure, its preparation method and its application.
- the present invention provides a class of compounds of general formula (I) or pharmaceutically acceptable salts thereof:
- Z -COOR 2 , -CONR 2 R 3 , or -NR 2 R 3 ;
- R 1 is independently taken from hydrogen, or alkyl (C ⁇ 8), alkyl ether group, or halogen substituted form of at least one hydrogen atom of any one of these groups;
- R 2 and R 3 are independently taken from hydrogen, or alkyl (C ⁇ 8), cycloalkyl (C ⁇ 8), spiroalkyl (C ⁇ 8), alkenyl (C ⁇ 8), alkynyl ( C ⁇ 8), aryl (C ⁇ 8), heteroaryl (C ⁇ 8, where at least one of the ring atoms is nitrogen, oxygen or sulfur), aralkyl (C ⁇ 8), alkyl ether group, or these At least one hydrogen atom of any one of the groups is substituted by halogen, hydroxyl, amino, or carboxyl.
- the compound is further defined as a type of compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof:
- Z -COOR 1 , -CONR 1 R 2 , or -NR 1 R 2 ;
- R 1 and R 2 are independently taken from hydrogen, or alkyl (C ⁇ 8), cycloalkyl (C ⁇ 8), spiroalkyl (C ⁇ 8), alkenyl (C ⁇ 8), alkynyl ( C ⁇ 8), aryl (C ⁇ 8), heteroaryl (C ⁇ 8, where at least one of the ring atoms is nitrogen, oxygen or sulfur), aralkyl (C ⁇ 8), alkyl ether group, or these At least one hydrogen atom of any one of the groups is substituted by halogen, hydroxyl, amino, or carboxyl.
- the compound is further defined as a type of compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof:
- Z -COOR 1 , -CONR 1 R 2 , or -NR 1 R 2 ;
- R 1 and R 2 are independently taken from hydrogen, or alkyl (C ⁇ 8), cycloalkyl (C ⁇ 8), spiroalkyl (C ⁇ 8), alkenyl (C ⁇ 8), alkynyl ( C ⁇ 8), aryl (C ⁇ 8), heteroaryl (C ⁇ 8, where at least one of the ring atoms is nitrogen, oxygen or sulfur), aralkyl (C ⁇ 8), alkyl ether group, or these At least one hydrogen atom of any one of the groups is substituted by halogen, hydroxyl, or amino.
- the compound is further defined as a type of compound represented by the general formula (IV) or a pharmaceutically acceptable salt thereof:
- Z -COOCH 3 , -CONHCH 2 CF 3 or -NHCOCF 2 CH 3 ;
- R 1 is taken from alkyl (C ⁇ 8), cycloalkyl (C ⁇ 8), spiroalkyl (C ⁇ 8), alkenyl (C ⁇ 8), alkynyl (C ⁇ 8), aryl ( C ⁇ 8), heteroaryl (C ⁇ 8, wherein at least one of the ring atoms is nitrogen, oxygen or sulfur), aralkyl (C ⁇ 8), alkyl ether group, or at least one of any of these groups
- the compound is further defined as a type of compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof:
- Z -COOCH 3 , -CONHCH 2 CF 3 or -NHCOCF 2 CH 3 ;
- R 1 is taken from alkyl (C ⁇ 8), cycloalkyl (C ⁇ 8), alkenyl (C ⁇ 8), alkynyl (C ⁇ 8), aryl (C ⁇ 8), heteroaryl ( C ⁇ 8, where at least one of the ring atoms is nitrogen, oxygen or sulfur), aralkyl (C ⁇ 8), alkyl ether group, or halogen, hydroxyl, or amino substitution of at least one hydrogen atom of any of these groups form.
- Non-limiting examples of the compounds provided in the present disclosure include compounds according to the chemical formula shown below, and pharmaceutically acceptable salts thereof:
- some compounds can be selected by the following synthesis method (1) to construct a C-ring conjugated diene structure:
- some compounds can also be selected to construct the C-ring conjugated diene structure by the following synthesis method (2):
- some compounds can also be selected to construct the C-ring conjugated diene structure by the following synthesis method (3):
- the above-mentioned compounds themselves, or optical isomers, and pharmaceutically acceptable salts possess anti-inflammatory activity at low concentration (nM) and anti-tumor activity at high concentration ( ⁇ M).
- the above-mentioned compounds themselves, or optical isomers, and pharmaceutically acceptable salts have applications in the treatment of inflammatory-related diseases, tumors and other diseases.
- the amount of the compound itself, or an optical isomer, or a pharmaceutically acceptable salt in the application is about 0.01 mg to about 1000 mg, about 0.1 mg to about 200 mg, about 1 mg to about 100 mg, and about 5 mg to about 5 mg. About 30 mg, about 10 mg to about 20 mg, about 12 mg to about 18 mg, or about 15 mg.
- the present invention also provides a pharmaceutical composition.
- the compound disclosed herein can be administered as a pure chemical, but is preferably administered as a pharmaceutical composition. Therefore, the present invention provides a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt together with at least one pharmaceutically acceptable carrier.
- the pharmaceutical composition may contain the compound or salt as the sole active agent, and may also contain at least one other active agent.
- the compounds disclosed in the present invention can be injected, orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, by oral cavity, rectal, as an ophthalmic solution, or via a dosage unit formulation containing conventional pharmaceutical carriers.
- the pharmaceutical composition can be formulated into any pharmaceutical form, such as: injection, aerosol, cream, gel, pill, capsule, tablet, syrup, transdermal patch, or ophthalmic solution.
- Some dosage forms such as tablets and capsules can be subdivided into appropriate dosage unit dosage forms containing appropriate amounts of active ingredients such as effective amounts for the desired purpose.
- Injection preparations preferably include injections, powder injections, etc., and are preferably injected intravenously, intramuscularly or locally.
- Carriers include excipients and diluents, and must have sufficiently high purity and very low toxicity to make them suitable for administration to the patient to be treated.
- the carrier may be inert or it may have medicinal benefits on its own.
- the types of carriers include, but are not limited to: binders, buffers, colorants, diluents, disintegrants, emulsifiers, flavoring agents, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents Agent, and wetting agent.
- Some carriers can be listed in more than one category, for example, vegetable oils can be used as lubricants in some formulations and as diluents in others.
- Exemplary pharmaceutical carriers include sugar, starch, cellulose, malt, gelatin, talc and vegetable oils.
- An optional active agent may be included in the pharmaceutical composition, which does not substantially affect the activity of the compound of the present invention.
- Optical isomers are compounds that have the same chemical composition but differ in the arrangement of atoms or groups in space. It includes “diastereomers” and “enantiomers”.
- Alkyl includes both branched and straight chain saturated aliphatic hydrocarbon groups, and has a specified number of carbon atoms, generally 1 to about 12 carbon atoms.
- alkyl (C ⁇ 8) as used herein denotes an alkyl group having 1 to 8 carbon atoms. Examples of alkyl groups include, but are not limited to: methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, tert-butyl, n-pentyl, and sec-pentyl.
- Cycloalkyl includes monocyclic, bicyclic or tricyclic alkyl groups, which usually have 3 to 12 carbon atoms. Cycloalkyl (C ⁇ 8) refers to having 3 to 8 carbon atoms, such as 3 to 8, or 3 to 4, 3 to 5, 3 to 6, or 3 to 7 carbon atoms. Exemplary monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Bicyclic and tricyclic ring systems include both bridged cycloalkyls and fused rings, such as, but not limited to, bicyclic [2.1.1] hexane and the like.
- Cycloalkyl groups can be substituted or unsubstituted.
- the substituted cycloalkyl group may be substituted one or more times with non-hydrogen and non-carbon groups as defined above.
- substituted cycloalkyl groups may also include those rings substituted with straight or branched chain alkyl groups as defined above.
- Representative substituted cycloalkyl groups can be mono-substituted or substituted more than once, for example, but not limited to, 2,2-, 2,3-, 2,4-, 2,5-, or 2,6- Disubstituted cyclohexyl, which may be substituted with substituents such as those listed above.
- Alkenyl (C ⁇ 8) “alkenyl” refers to straight and branched hydrocarbon chains that include one or more unsaturated carbon-carbon bonds. The carbon-carbon bonds can occur at any stable point along the chain.
- the alkenyl group (C ⁇ 8) described herein generally has 2 to 8 carbon atoms, such as C 2 -C 8 , C 2 -C 6 , and C 2 -C 4 alkenyl. In some embodiments, the alkenyl group includes one, two, or three carbon-carbon double bonds.
- Alkenyl groups can be substituted or unsubstituted. Representative substituted alkenyl groups may be mono-substituted or substituted more than once, for example, but not limited to, mono-, di- or tri-substituted alkenyl groups substituted with substituents such as those listed above.
- Aryl is a cyclic aromatic hydrocarbon that does not contain heteroatoms.
- the aryl group described herein includes monocyclic, bicyclic and tricyclic ring systems.
- aryl groups include, but are not limited to, phenyl, azulenyl, heptyl, diphenyl, fluorenyl, phenanthryl, anthracenyl, indenyl, dihydroindenyl, pentacyclopentadienyl, and naphthyl.
- the aryl group contains 6-14 carbon atoms in the ring portion of the group, and in other embodiments, it contains 6-12 carbon atoms or even 6-10 carbon atoms.
- aryl groups are phenyl and naphthyl.
- aryl includes those groups that contain fused rings, such as fused aryl-aliphatic ring systems (e.g., indenyl, tetrahydronaphthyl, etc.).
- fused aryl-aliphatic ring systems e.g., indenyl, tetrahydronaphthyl, etc.
- aryl also includes substituted aryl groups. Groups such as tolyl are called substituted aryl groups. Representative substituted aryl groups can be mono-substituted and substituted more than once.
- monosubstituted aryl groups include, but are not limited to, 2-substituted, 3-substituted, 4-substituted, 5-substituted, or 6-substituted phenyl or naphthyl, which can be substituted by such as those listed above
- the substituents and other substituents are substituted.
- the aryl group is a phenyl group, which may be substituted or unsubstituted.
- the substituted phenyl group has one or two substituents.
- the substituted phenyl has one substituent.
- Heteroaryl means a stable 5- or 6-membered monocyclic or polycyclic ring containing 1 to 4, or preferably 1 to 3 heteroatoms selected from N, O, and S, and the remaining ring atoms are carbon.
- heteroaryl groups include, but are not limited to: pyridinyl, indolyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl, oxazolyl, furyl, thiophenyl, thiazolyl, triazolyl, tetrazolyl, Azolyl, isoxazolyl, quinolinyl, pyrrolyl, pyrazolyl, benzo[b]phenylthio, isoquinolinyl, quinazolinyl, quinoxalinyl, thienyl, isoindolyl , And 5,6,7,8-tetrahydroisoquinoline.
- Alkynyl includes straight and branched chain alkyl groups as defined above, except that there is at least one triple bond between two carbon atoms.
- the alkynyl group (C ⁇ 8) has 2-8 carbon atoms, and in some embodiments, 2-8, 2-6, or 2-4 carbon atoms.
- the alkynyl group includes one, two, or three carbon-carbon triple bonds. Examples include but are not limited to -C ⁇ CH, -C ⁇ CCH 3 , -CH 2 C ⁇ CCH 3 , -C ⁇ CCH 2 CH(CH 2 CH 3 ) 2 and so on.
- Alkynyl groups can be substituted or unsubstituted.
- Representative substituted alkynyl groups may be mono-substituted or substituted more than once, for example, but not limited to, mono-, di- or tri-substituted alkynyl groups substituted with substituents such as those listed above .
- Alkyl is an alkyl group as defined above, wherein the hydrogen or carbon bond of the alkyl group is replaced by a bond to the aryl group as defined above.
- the aralkyl group (C ⁇ 8) has 7 to 8 carbon atoms.
- Aralkyl groups can be substituted or unsubstituted.
- the substituted aralkyl group can be substituted in the alkyl part, the aryl part, or both the alkyl and aryl parts of the group.
- Representative aralkyl groups include, but are not limited to, benzyl and phenethyl.
- Representative substituted aralkyl groups may be substituted one or more times with substituents such as those listed above.
- Alkyl ether group refers to any alkyl group as defined above in which at least one carbon-carbon bond is replaced with a carbon-oxygen bond.
- the carbon-oxygen bond can be on the terminal (as in an alkoxy group) or the carbon-oxygen bond can be internal (ie, C-O-C).
- Alkyl ethers contain at least one carbon-oxygen bond, but may include more than one carbon-oxygen bond.
- polyethylene glycol (PEG) is included within the meaning of alkyl ether.
- alkyl ether groups are optionally substituted.
- the alkyl ether is substituted with an alcohol or phosphate ester.
- spiroalkyl refers to a structure composed of two cycloalkyl moieties with exactly one atom in common. Examples include, but are not limited to, spiro[2.3]hexyl, spiro[2.5]octane and the like.
- halogen refers to bromine, chlorine, fluorine, or iodine.
- hydroxyl may refer to -OH or its ionized form -O - .
- amino refers to a functional group having a nitrogen atom and 1 to 2 hydrogen atoms.
- Amino groups are generally used herein to describe primary, secondary, or tertiary amines, and those skilled in the art can determine their identity in view of the context in which the term is used in this disclosure.
- the term “amine” or “amine group” or “amino group” means a functional group containing a nitrogen atom derived from ammonia (NH 3 ).
- the amine group may be a primary amine, which means that the nitrogen is bonded to two hydrogen atoms and a substituent that includes a substituted or unsubstituted alkyl or aryl group or an aliphatic or aromatic group.
- the amine group may be a secondary amine, which means that the nitrogen is bonded to one hydrogen atom and two substituents, the substituents including substituted or unsubstituted alkyl or aryl groups or aliphatic or aromatic groups, This is defined as follows.
- the amine group may be a tertiary amine, which means that the nitrogen is bonded to three substituents, which include substituted or unsubstituted alkyl or aryl groups or aliphatic or aromatic groups.
- the amine group may also be a quaternary amine, which means that the designated amine group is bonded to the fourth group to form a positively charged ammonium group.
- Carboxyl refers to the -C(O)OH group or its ionized form: -C(O)O - .
- “Pharmaceutically acceptable salt” or “salt of a compound” is a derivative of the disclosed compound, wherein the parent compound is modified by preparing a non-toxic acid or base addition salt thereof, and also refers to these compounds and these salts
- Examples of pharmaceutically acceptable salts include, but are not limited to: inorganic or organic acid addition salts of basic residues such as amines; alkali or organic addition salts of acidic residues such as carboxylic acids; etc., and include one or more Combinations of the above salts.
- Pharmaceutically acceptable salts include non-toxic salts and quaternary ammonium salts such as parent compounds formed from non-toxic inorganic or organic acids.
- non-toxic acid salts include those derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, etc.; other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, Cesium salt, etc.; alkaline earth metal salt such as: calcium salt, magnesium salt, etc., and a combination including one or more of the above-mentioned salts.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, etc.
- other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, Cesium salt, etc.
- alkaline earth metal salt such as: calcium salt, magnesium salt, etc., and a combination including one or more of the above-mentioned salts.
- Organic salts include compounds such as acetic acid, trifluoroacetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, catabolic acid, maleic acid, hydroxymaleic acid, benzene Acetic acid, glutamic acid, benzoic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid, fumaric acid, p-toluenesulfonic acid, methanesulfonic acid , Ethane disulfonic acid, oxalic acid, isethionic acid, HOOC-(CH 2 )n-COOH (where n is 0 to 4) and other organic acid salts; organic amine salts, such as: triethylamine salt, Pyridine
- Figure 1 shows the co-crystal structure analysis and structural modification prediction of the BTB region protein of RTA401 and the target protein Keap1.
- Fig. 2 is an MS spectrum of a representative compound 1 having a C ring of a conjugated diene structure.
- Fig. 3 is a 1 H NMR spectrum of a representative compound 1 having a C ring of a conjugated diene structure.
- Fig. 4 is an MS spectrum of the representative compound 7 with the C ring of the substituted conjugated diene structure.
- Fig. 5 is a 1 H NMR chart of a representative compound 7 having a ring C of a conjugated diene structure with a substituent.
- Fig. 6 is the rigid structure region (gray region) of the C ring core of the conjugated diene structure with substituents.
- the embodiment of the present invention provides an oleanane compound with a C ring of a conjugated diene rigid structure, and a synthesis method and biological activity screening thereof.
- the fine structure of the compound C ring has an extremely important influence on the activity of the compound.
- the available data show that, without the enol-like conjugated structure, OA-26 reduces the anti-inflammatory activity of RTA401 compound by 1000 times [J.Med.Chem.2000,43,4233-4246].
- the structure of the compound C ring is affected by the large steric hindrance of the surrounding multi-ring rigid structure, which makes its reactivity significantly passivated.
- the C-cyclic ethylenic bond of oleanolic acid (OA) does not react at all under atmospheric catalytic hydrogenation conditions.
- the A-ring ethylenic bond of OA-20 can be reduced quantitatively, but the C-ring ethylenic bond can not be reacted at all, and the final compound is OA-19. Therefore, it can be seen that the C ring possesses the unique chemical properties of natural terpenoid products.
- Synthetic reagents and conditions a) hydrogen, palladium on carbon, tetrahydrofuran, normal pressure and normal temperature, 24 to 48 hours.
- Synthetic reagents and conditions a) benzyl chloride, potassium carbonate, N,N-dimethylformamide, 55°C, 5 hours; b) acetic anhydride, pyridine, 0°C ⁇ room temperature, 4 hours; c) 30% hydrogen peroxide , Formic acid, dichloromethane, room temperature, 24 hours; d) bromine, hydrobromic acid, acetic acid, 50 °C ⁇ room temperature, 24 hours; e) potassium hydroxide, methanol, reflux, 54 minutes; f) Jones reagent, acetone, 0°C ⁇ room temperature, 20 minutes; g) ethyl formate, sodium methoxide, dichloromethane, 0°C ⁇ room temperature, 12 hours; h) hydroxylamine hydrochloride, ethanol, reflux, 1 hour; i) zinc amalgam reagent, acetone, Room temperature, 4 hours; j) Sodium methoxide, ether, methanol, 0°C ⁇ room
- the white solid (2.1 g, 3.74 mmol) obtained in the previous step was dissolved in a mixed solution of methanol (60 mL) and ether (125 mL), sodium methoxide (6.38 g, 118 mmol) was added at 0°C, and the reaction was carried out at room temperature for 45 minutes.
- the reaction solution was diluted with dichloromethane (50 mL), and the organic layer was washed 3 times with 5% dilute hydrochloric acid, saturated sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a pale yellow solid OA-10 ( 2.0g, 95%).
- Synthesis reagents and conditions a) hydrogen, palladium on carbon, tetrahydrofuran, normal pressure and room temperature, 1 to 2 hours; b) methyl iodide, potassium carbonate, acetone, room temperature, 4 hours; c) zinc amalgam reagent, acetone, room temperature, 4 Hours; d) sodium methoxide, ether, methanol, 0°C ⁇ room temperature, 1 hour; e) 2,3-dichloro-5,6-dicyanoquinone, benzene, reflux, 20 minutes.
- OA-8 was used as the starting material to prepare OA-11, and the preparation method was completed according to the previous study [CN102070697A].
- Compound OA-11 (1.05g, 2.1mmol) was dissolved in acetone (50mL), potassium carbonate (3.0g, 21mmol) was added and suspended in the solution, stirred vigorously for 2 hours, and slowly added dropwise methyl iodide (0.85g, 6mmol), react at room temperature for 5 hours.
- the reaction solution was filtered, the filtrate was concentrated, and dichloromethane (50mL) was diluted.
- Synthetic reagents and conditions a) zinc amalgam reagent, acetone, room temperature, 4 hours; b) sodium methoxide, ether, methanol, 0°C ⁇ room temperature, 1 hour; c) 2,3-dichloro-5,6-di Cyano-p-benzoquinone, benzene, reflux, 20 minutes; d)i. Oxalyl chloride, anhydrous dichloromethane, 0°C ⁇ room temperature, 12 hours; ii. NH 2 CH 2 CF 3 , triethylamine, anhydrous dichloride Methane, 0°C ⁇ room temperature, 4 hours.
- Dissolve compound 3 (1.4g, 3.04mmol) in anhydrous dichloromethane (5mL), add oxalyl chloride (3.86g, 30.4mmol) at 0°C, stir, return to room temperature, react overnight, spin dry to obtain a pale yellow solid , Directly into the next reaction.
- the solid obtained in the previous step was dissolved in anhydrous dichloromethane (5mL).
- Trifluoroethylamine (0.36g, 3.64mmol) and triethylamine (0.92g, 9.12mmol) were added at 0°C, stirred, returned to room temperature, and reacted.
- Synthesis reagents and conditions a) Sodium methoxide, ether, methanol, 0°C ⁇ room temperature, 1 hour; b) 2,3-Dichloro-5,6-dicyano-p-benzoquinone, benzene, reflux, 20 minutes; c) Acetic anhydride, concentrated sulfuric acid, p-toluenesulfonic acid, room temperature, 2 hours.
- Synthesis reagents and conditions a) Sodium methoxide, ether, methanol, 0°C ⁇ room temperature, 1 hour; b) 2,3-Dichloro-5,6-dicyano-p-benzoquinone, benzene, reflux, 20 minutes; c) Acetic anhydride, concentrated sulfuric acid, p-toluenesulfonic acid, room temperature, 2 hours.
- Synthesis reagents and conditions a) methyl iodide, potassium carbonate, acetone, room temperature, 4 hours; b) acetic anhydride, concentrated sulfuric acid, p-toluenesulfonic acid, room temperature, 2 hours.
- the preparation of OA-21 from compound OA-20 was completed by referring to the method of preparing OA-12 from OA-11 in Example 2 of the present invention.
- the preparation of compound 7 from compound OA-21 is completed by referring to the method of preparing compound 5 from OA-18 in Example 4 of the present invention.
- MS[M+H] + of compound 7 calcd for C 34 H 46 NO 5 , 548.3; found 548.5; MS [M+NH 4 ] + : calcd for C 34 H 49 N 2 O 5 , 565.4; found 565.6.
- Synthesis reagents and conditions a) i. Oxalyl chloride, anhydrous dichloromethane, 0°C ⁇ room temperature, 12 hours; ii.NH 2 CH 3 , triethylamine, anhydrous dichloromethane, 0°C ⁇ room temperature, 4 hours B) i. Oxalyl chloride, anhydrous dichloromethane, 0°C ⁇ room temperature, 12 hours; ii. NH 2 CH 2 CF 3 , triethylamine, anhydrous dichloromethane, 0°C ⁇ room temperature, 4 hours; c )i. Oxalyl chloride, anhydrous dichloromethane, 0°C ⁇ room temperature, 12 hours; ii.
- the preparation of OA-22, OA-23 and OA-24 from compound OA-20 was completed by referring to the method of preparing compound 4 from compound 3 in Example 3 of the present invention.
- the preparation of compounds 8, 9 and 10 from compounds OA-22, OA-23 and OA-24, respectively, was completed with reference to the method for preparing compound 5 from OA-18 in Example 4 of the present invention.
- Synthesis reagents and conditions a) Acetic anhydride, concentrated sulfuric acid, p-toluenesulfonic acid, room temperature, 2 hours.
- Compound OA-25 was prepared from OA-20 with reference to CN104395332B.
- the preparation of compound 11 from compound OA-25 was completed by referring to the method of preparing compound 5 from OA-18 in Example 4 of the present invention.
- MS[M+H] + of compound 11 calcd for C 35 H 47 F 2 N 2 O 4 , 597.4; found 597.4.
- Synthesis reagents and conditions a) Anhydrous tetrahydrofuran, lithium diisopropylamine solution, chloroacetic anhydride, -78°C, 2-4 hours.
- Synthetic reagents and conditions a) Anhydrous tetrahydrofuran, lithium diisopropylamide solution, isobutyryl chloride, -78°C, 2-4 hours.
- compound 13 was prepared from compound OA-21 in a small amount. MS[M+H] + of compound 13: calcd for C 36 H 50 NO 5 , 576.3; found 576.4.
- Synthetic reagents and conditions a) Anhydrous tetrahydrofuran, lithium diisopropylamide solution, isobutyryl chloride, -78°C, 2-4 hours.
- compound 14 was prepared from compound OA-21. MS[M+H] + of compound 14: calcd for C 36 H 48 NO 6 ,590.3; found 590.3.
- the results of the determination of the inhibition of IFN ⁇ -induced nitric oxide production by RAW264.7 mouse macrophages by several compounds of the present invention were carried out with reference to the document J. Med. Chem. 2000, 43, 4233-4246. 20,000 cells/well were seeded in RPMI1640 medium and 0.5% FBS in a 96-well plate, and incubated at 37° C. and 5% CO 2. DMSO or test compound and recombinant mouse IFN ⁇ were treated together for 48 hours. Griess reagent is used to react with nitric oxide in the medium and detected at 550 nM. In this way, the anti-inflammatory biological activity of the compound was initially screened.
- a "-" means IC 50 is greater than 100nM
- IC 50 is between 10 and 100nM
- b OA-26 is a known compound, prepared according to the document J. Med. Chem. 2000, 43, 4233-4246.
- Example 14 Based on the screening model in Example 14, before adding DMSO or test compound 7 or 12, add a known cell esterase inhibitor (for example, 1mmol/L Paraoxon) [J.Appl.Toxicol.2005,25,562–67] , And then also use Griess reagent to react with nitric oxide in the medium and detect at 550nM. In this way, the interaction between the esterase inhibitor and the test compound is tested.
- the results show (see Table 2), which represents that the anti-inflammatory biological activity produced by compounds 7 and 12 is completely independent of the presence of esterase.
- a "-" means IC 50 is greater than 100nM
- IC 50 is between 10 and 100nM
- Human pancreatic cancer PANC-1 cells were seeded in a 96-well plate at a density of 3000 cells/well with 100 ⁇ L of culture medium. Add the required drug concentration to the culture medium, shake and mix, and each drug concentration is at least three replicate holes. After 72 hours, discard the culture medium, add 60 ⁇ L of 50% TCA to each well, let stand for 60 minutes at 4°C, wash with deionized water, and dry naturally; add 60 ⁇ L of 0.4% SRB to each well, and keep it at room temperature away from light.
- the cell proliferation inhibition rate (%) (1-OD experimental group /OD solvent group )*100%.
- the experimental results are shown in Table 3 below.
- Most of the compounds can inhibit the proliferation of human pancreatic cancer PANC-1 cells at the micromolar level.
- the electron-withdrawing substituent side chain can significantly enhance the anti-tumor biological activity of the compound.
- compound 11 And 12 compared with RTA402, the biological activity has a significant difference (P ⁇ 0.05).
- a "-" means IC 50 is greater than 100 ⁇ M
- IC 50 is between 10 and 100 ⁇ M
- b OA-26 is a known compound, prepared according to the document J. Med. Chem. 2000, 43, 4233-4246.
- the toxicity of compounds 7 and 12 at the IC 50 concentration level of anti-tumor and anti-inflammatory on human normal cells representative LO2 hepatocytes was investigated.
- the logarithmic growth phase cells were seeded in a 96-well plate (100 ⁇ L/well) at a cell density of 8 ⁇ 10 3 cells per well, and placed in a cell incubator for culture.
- different concentrations of test compounds were added to the culture medium, and each group had 4 multiple wells. Put the cells back into the CO 2 incubator for culture.
- test compound After 24 hours, discard the cell culture medium, add 200 ⁇ L of medium containing 10% MTT (5mg/mL), continue incubating for 4 hours in the 37°C incubator, discard the medium containing MTT, and then add 150 ⁇ L of DMSO to each well , Shake for 8min to fully dissolve the formed formazan.
- the results are shown in Table 4.
- the test compound has little inhibitory activity against normal cells at the concentration level of anti-tumor (1-10 ⁇ M), and has good tumor cell/normal cell selectivity; while at the concentration of anti-inflammatory activity (Around 10 nM), no inhibitory activity was seen at all.
- compounds 7 and 12 the toxicity to human normal cells is slightly reduced or equivalent, and there is no significant inhibitory effect on human normal cells at therapeutic concentrations.
- a "-" means that the inhibition rate is less than or equal to 0%, and there is no cell proliferation inhibition at all.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物 | 生物活性 a | 化合物 | 生物活性 a |
RTA402 | ++ | 8 | ++ |
1 | - | 9 | +++ |
2 | + | 10 | ++ |
3 | - | 11 | +++ |
4 | ++ | 12 | ++++ |
5 | ++ | 13 | + |
6 | ++ | 14 | + |
7 | +++ | OA-26 b | - |
化合物 | 生物活性 a | 化合物 | 生物活性 a |
RTA402+Paraoxon | ++ | Paraoxon | - |
7+Paraoxon | +++ | 12+Paraoxon | ++++ |
化合物 | 生物活性 a | 化合物 | 生物活性 a |
RTA402 | ++ | 8 | ++ |
1 | - | 9 | ++ |
2 | - | 10 | ++ |
3 | - | 11 | +++ |
4 | + | 12 | +++ |
5 | + | 13 | + |
6 | + | 14 | + |
7 | ++ | OA-26 b | - |
Claims (10)
- 药物组合物,其特征在于,包含有效量的权利要求1-6任一所述的化合物或其药学上可接受的盐、以及药学上可接受的载体。
- 根据权利要求1-6任一所述的化合物或其药学上可接受的盐、根据权利要求7所述的药物组合物在制备治疗炎性相关疾病药物中的应用。
- 根据权利要求1-6任一所述的化合物或其药学上可接受的盐、根据权利要求7所述的药物组合物在制备治疗抗肿瘤活性药物中的应用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010158063 | 2020-03-09 | ||
CN202010158063.5 | 2020-03-09 | ||
CN202010306785.0 | 2020-04-17 | ||
CN202010306785.0A CN111393500B (zh) | 2020-03-09 | 2020-04-17 | 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021179884A1 true WO2021179884A1 (zh) | 2021-09-16 |
Family
ID=71425276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/076726 WO2021179884A1 (zh) | 2020-03-09 | 2021-02-18 | 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111393500B (zh) |
WO (1) | WO2021179884A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111393500B (zh) * | 2020-03-09 | 2021-09-28 | 丁晔 | 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1796401A (zh) * | 2004-12-29 | 2006-07-05 | 浙江海正天华新药研发有限公司 | 五环三萜类衍生物及其制备方法和用途 |
CN101153030A (zh) * | 2006-09-29 | 2008-04-02 | 中国科学院成都生物研究所 | 多取代氢化萘化合物、其制备方法及用途 |
WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
CN103665087A (zh) * | 2012-09-03 | 2014-03-26 | 上海源力生物技术有限公司 | 一种萜类化合物及其在医药上的应用 |
CN103897011A (zh) * | 2014-04-10 | 2014-07-02 | 中国药科大学 | 一类cddo咪唑衍生物、其制备方法和用途 |
CN111393500A (zh) * | 2020-03-09 | 2020-07-10 | 丁晔 | 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9110929D0 (en) * | 1991-05-21 | 1991-07-10 | Idb Holding Spa | Ursane derivatives,their preparation and pharmaceutical formulations thereof |
CN101235069A (zh) * | 2004-12-29 | 2008-08-06 | 浙江大学 | C环上具有羰基和氧取代基的齐墩果烷衍生物及用途 |
CN101235071B (zh) * | 2004-12-29 | 2013-02-06 | 浙江大学 | 一类双烯齐墩果酸五环三萜类衍生物及用途 |
CN101513420A (zh) * | 2008-12-25 | 2009-08-26 | 天津鼎沣盈华进出口贸易有限公司 | 28-羟基-齐墩果烷-2,9(11),12-三烯在制备治疗皮肤疾病药物中的应用 |
US8981144B2 (en) * | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
US9896475B2 (en) * | 2014-08-26 | 2018-02-20 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
-
2020
- 2020-04-17 CN CN202010306785.0A patent/CN111393500B/zh active Active
-
2021
- 2021-02-18 WO PCT/CN2021/076726 patent/WO2021179884A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1796401A (zh) * | 2004-12-29 | 2006-07-05 | 浙江海正天华新药研发有限公司 | 五环三萜类衍生物及其制备方法和用途 |
CN101153030A (zh) * | 2006-09-29 | 2008-04-02 | 中国科学院成都生物研究所 | 多取代氢化萘化合物、其制备方法及用途 |
WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
CN103665087A (zh) * | 2012-09-03 | 2014-03-26 | 上海源力生物技术有限公司 | 一种萜类化合物及其在医药上的应用 |
CN103897011A (zh) * | 2014-04-10 | 2014-07-02 | 中国药科大学 | 一类cddo咪唑衍生物、其制备方法和用途 |
CN111393500A (zh) * | 2020-03-09 | 2020-07-10 | 丁晔 | 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111393500B (zh) | 2021-09-28 |
CN111393500A (zh) | 2020-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102029951B1 (ko) | 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도 | |
JP2022523786A (ja) | ピラジン誘導体およびshp2の阻害の際のその適用 | |
US11878987B2 (en) | Heterocyclic compound as TRK inhibitor | |
KR20010042434A (ko) | 술폰아미드 함유 인돌 화합물 | |
WO2021083328A1 (zh) | 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途 | |
EP4310083A1 (en) | Furan fused ring-substituted glutarimide compound | |
CN112851663A (zh) | 一种并杂环化合物及其用途 | |
WO2022199547A1 (zh) | 一种7,9-二氢嘌呤衍生物及其制药用途 | |
JP2021513549A (ja) | インドール−2、3−ジオキシゲナーゼ阻害剤としてのスピロ化合物 | |
WO2021179884A1 (zh) | 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 | |
CN107501279B (zh) | 呋喃并喹啉二酮类化合物及其医药用途 | |
CN114195814A (zh) | 羟基萘酮-苯硼酸类化合物、制备方法和用途 | |
CN102584679B (zh) | 一类苯并咔唑酰胺类化合物、其制备方法和用途 | |
US6887864B2 (en) | Azepane derivatives | |
WO2022148439A1 (zh) | 作为bcl-2抑制剂的杂环化合物 | |
JPH0819095B2 (ja) | インドロキノン化合物 | |
CN111484495B (zh) | 含二氢蝶啶二酮骨架衍生物的制备方法和用途 | |
JP2022532416A (ja) | Parr阻害剤としてのキナゾリン―2.4―ジオン誘導体 | |
CN110526955A (zh) | 含异羟肟酸结构片段的18β-甘草次酸类化合物及其应用 | |
KR101035709B1 (ko) | 신규2-치환아미노알킬레닐옥시-3-치환페닐에티닐-6-아미노퀴녹살린 유도체 | |
CN108017639B (zh) | Ido抑制剂及其制备方法和应用 | |
CN113004268B (zh) | 一种抑制肿瘤细胞生长的噻唑化合物及其用途 | |
Venkatanarayana et al. | Ultrasound assisted effective synthesis of benzopril based indole derivatives, docking studies: And there in vitro anti-proliferative effects on various cancer cell lines | |
EP3543228A1 (en) | Compound having anticancer activity, and preparation method and application thereof | |
WO2019184919A1 (zh) | 一种含有金刚烷的化合物及其在治疗癌症中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21767568 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21767568 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21767568 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 05/07/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21767568 Country of ref document: EP Kind code of ref document: A1 |